Micrometastases in non-small cell lung cancer (NSCLC)

被引:0
|
作者
Passlick, B [1 ]
机构
[1] Univ Munich, Klinikum Innenstadt, Dept Surg, Div Thorac Surg, D-80336 Munich, Germany
关键词
micrometastases; NSCLC; immunohistochemical detection; isolated tumor cells; prognosis;
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Early metastasis is a well-known Feature of poor prognosis in potentially resectable non-small cell lung cancer (NSCLC). However. a significant number of lymph node-negative patients die early of metastatic disease. Therefore. it has to be assumed that in some patients an early tumor cell dissemination has occurred which is clearly underestimated by current staging procedures. Recently. it has been shown, that an early dissemination of individual carcinoma cells to regional lymph nodes or bone marrow can be detected by using sensitive immunocytochemical techniques with monoclonal antibodies against epithelium-specific proteins, The incidence of immunohistochemically positive patients varies between 30 and 70% depending on the type of primary tumor. the immunohistochemical staining procedure used and especially on the primary monoclonal antibody. The detection of disseminated tumor cells in lymph nodes or bone marrow by immunocytochemistry is associated with a poorer prognosis in lung cancer. In conclusion, the immunohistochemical detection of disseminated tumor cells in lymph nodes can help to obtain a more exact identification of patients with an unfavorable prognosis. Whether the identified patients will gain from an adjuvant therapy, has to be evaluated in further studies. (C) 2001 Elsevier Science Ireland Ltd. All rights reserved.
引用
收藏
页码:S25 / S29
页数:5
相关论文
共 50 条
  • [1] The clinical value of lymphatic micrometastases in patients with non-small cell lung cancer (NSCLC)
    Verhagen, A
    Shirango, H
    Thunnissen, E
    Tjan-Heijnen, V
    van der Drift, M
    van der Bruggen, W
    Bulten, H
    LUNG CANCER, 2005, 49 : S217 - S218
  • [2] β-catenin in non-small cell lung cancer (NSCLC)
    Swinson, DEB
    Lolljee, J
    Edwards, JG
    Jones, JL
    Cox, G
    Richardson, D
    O'Byrne, KJ
    BRITISH JOURNAL OF CANCER, 2002, 86 : S59 - S60
  • [3] Immunotherapy for non-small cell lung cancer (NSCLC)
    Frost, Nikolaj
    Reck, Martin
    INNERE MEDIZIN, 2022, 63 (07): : 709 - 716
  • [4] Treatment of non-small cell lung cancer (NSCLC)
    Zarogoulidis, Konstantinos
    Zarogoulidis, Paul
    Darwiche, Kaid
    Boutsikou, Efimia
    Machairiotis, Nikolaos
    Tsakiridis, Kosmas
    Katsikogiannis, Nikolaos
    Kougioumtzi, Ioanna
    Karapantzos, Ilias
    Huang, Haidong
    Spyratos, Dionysios
    JOURNAL OF THORACIC DISEASE, 2013, 5 : S389 - S396
  • [5] Genotyping Non-Small Cell Lung Cancer (NSCLC)
    Delia Campos-Parra, Alma
    Cruz-Rico, Graciela
    Arrieta, Oscar
    GACETA MEXICANA DE ONCOLOGIA, 2012, 11 (01): : 35 - 44
  • [6] Gemcitabine in Non-Small Cell Lung Cancer (NSCLC)
    Christian Manegold
    Petr Zatloukal
    Kurt Krejcy
    Johannes Blatter
    Investigational New Drugs, 2000, 18 : 29 - 42
  • [7] BRCAness in non-small cell lung cancer (NSCLC).
    Waqar, Saiama Naheed
    Devarakonda, Siddhartha H. K.
    Michel, Loren S.
    Maggi, Leonard B.
    Watson, Mark
    Guebert, Kalin
    Carpenter, Danielle
    Sleckman, Barry P.
    Govindan, Ramaswamy
    Morgensztern, Daniel
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [8] Eicosanoids in non-small cell lung cancer (NSCLC)
    Johnson, D. H.
    Horn, L.
    Zhao, Z.
    Milne, G.
    Morrow, J.
    Sandler, A.
    Shyr, Y.
    Carbone, D. P.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [9] Gemcitabine in non-small cell lung cancer (NSCLC)
    Manegold, C
    Zatloukal, P
    Krejcy, K
    Blatter, J
    INVESTIGATIONAL NEW DRUGS, 2000, 18 (01) : 29 - 42
  • [10] Bone marrow isolated micrometastases of non-small cell lung cancer
    Dancewicz, M
    Kowaleski, J
    Sir, J
    Windorbska, W
    Ziolkowska, E
    Ostrowski, A
    LUNG CANCER, 2005, 49 : S209 - S210